- Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics
-
Konishi I, Abiko K, Hayashi T, Yamanoi K, Murakami R, Yamaguchi K, Hamanishi J, Baba T, Matsumura N, Mandai M, Kyoto Study Group for Ovarian Cancer Research
- KMID: 2537916
- J Gynecol Oncol.
- 2022 Sep;33(5):e83.
- doi: 10.3802/jgo.2022.33.e83
Epithelial ovarian cancer remains the lethal gynecological malignancy in women. The representative histotype is high-grade serous carcinoma (HGSC), and most patients with HGSC present at advanced stages with peritoneal dissemination.... -
- CITED
-
- Close
- SHARE
-
- Close
- Tissue Engineering with Compact Bone-Derived Cell Spheroids Enables Bone Formation around Transplanted Tooth
-
Matsumura N, Li X, Uchikawa-Kitaya E, Li N, Dong H, Chen K, Yoshizawa M, Kagami H
- KMID: 2528131
- Tissue Eng Regen Med.
- 2022 Apr;19(2):377-387.
- doi: 10.1007/s13770-021-00423-3
BACKGROUND: Although tooth transplantation is a desirable treatment option for congenital defects of permanent teeth in children, transplantation to a narrow alveolar ridge is not feasible. In this study, we... -
- CITED
-
- Close
- SHARE
-
- Close
- The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer
-
Tokunaga H, Mikami M, Nagase S, Kobayashi Y, Tabata T, Kaneuchi M, Satoh T, Hirashima Y, Matsumura N, Yokoyama Y, Kawana K, Kyo S, Aoki D, Katabuchi H
- KMID: 2526387
- J Gynecol Oncol.
- 2021 Mar;32(2):e49.
- doi: 10.3802/jgo.2021.32.e49
The fifth edition of the Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer was published in 2020. The guidelines... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052)
-
Asano H, Oda K, Yoshihara K, Ito YM, Matsumura N, Shimada M, Watari H, Enomoto T
- KMID: 2537899
- J Gynecol Oncol.
- 2022 Jul;33(4):e55.
- doi: 10.3802/jgo.2022.33.e55
Background Poly (adenosine diphosphate)-ribose polymerase (PARP) inhibitors for tumors with homologous recombination deficiency (HRD), including pathogenic mutations in BRCA1/2, have been developed. Genomic analysis revealed that about 20% of uterine leiomyosarcoma... -
- CITED
-
- Close
- SHARE
-
- Close
